Olanzapina (Olanzapine)

Olanzapine, the active ingredient in Olanzapina, is an atypical antipsychotic presented as a 10 mg tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olanzapina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions.

- Schizophrenia: helps control delusions, hallucinations and thought disorder. - Bipolar I disorder (manic episodes): reduces manic symptoms and stabilises mood. - Schizoaffective disorder: alleviates both psychotic and mood components. - Maintenance therapy for schizophrenia: helps prevent relapse after acute treatment. - Adjunctive treatment in major depressive disorder with psychotic features: augments antidepressant response.

Olanzapine may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being overly sleepy. - Dry mouth: reduced salivary flow. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: drop in blood pressure upon standing. - Elevated prolactin: mild hormonal changes.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Severe hyperglycaemia or new‑onset diabetes mellitus. - Agranulocytosis: dangerously low white‑blood cell count. - Myocardial infarction or other cardiac events. - Seizures: especially in patients with prior seizure history.

When prescribing Olanzapine, clinicians should evaluate patient history and monitor for specific safety concerns.

- Metabolic monitoring: regularly check weight, fasting glucose and lipid profile. - Cardiovascular assessment: monitor blood pressure and heart rate, especially at treatment initiation. - CNS effects: advise patients about sedation and avoid operating heavy machinery until they know how the drug affects them. - Pregnancy and lactation: use only if the potential benefit outweighs risk; discuss with obstetric specialist. - Elderly patients with dementia: avoid due to increased risk of mortality. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olanzapine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels and risk of toxicity. - CNS depressants: additive sedation with alcohol, benzodiazepines or opio opioids. - Anticholinergic agents: may exacerbate dry mouth and constipation.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce olanzapine concentrations. - Smoking: induces CYP1A2 and can lower drug exposure. - QT‑prolonging drugs: combined use may increase risk of cardiac arrhythmias.